title: Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma.
abstract: High-dose chemotherapy followed by autologous hematopoietic cell transplantation continues to play an integral role in the treatment strategy in patients with newly diagnosed multiple myeloma. Incorporation of newer potent anti-myeloma agents has further improved outcomes. However, disease relapse or progression remains a challenge after autologous transplantation. Allogeneic hematopoietic cell transplantation remains the only potentially curative modality for some patients due in part to graft-versus-myeloma effect. High transplant-related mortality, in the range of 30% to 40%, previously seen with myeloablative conditioning regimens, including total body irradiation plus cyclophosphamide has been significantly reduced by introducing less ablative preparative regimens, so called reduced-intensity conditioning. Cumulative evidence suggests encouraging prospects for allogeneic transplantation through improved outcomes of myeloma patients (overall survival exceeding 70% at 2 years in some studies); however, which patient population would benefit most from this treatment remains to be defined. newer strategies to augment graft-versus-myeloma effect and minimize post transplant toxicities are in need of further improvement in patients with myeloma.
authors: Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida,Tampa, FL, USA. taiga.nishihori@moffitt.org
authors: T
authors: T
authors: Nishihori
authors: M A
authors: MA
authors: Kharfan-Dabaja
authors: J L
authors: JL
authors: Ochoa-Bayona
authors: A
authors: A
authors: Bazarbachi
authors: M
authors: M
authors: Pasquini
authors: M
authors: M
authors: Alsina
mesh_terms: D002986:Clinical Trials as Topic; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous / Q000009:adverse effects